Skip to main content

Lupus

Variable Pregnancy Outcomes with Belimumab in SLE An analysis looked at outcomes in pregnant SLE exposed to belimumab reported there are few pregnancies and confounding disease and comorbidity factors to provide clear guidance for such patients. https://t.co/nBzoyL4cHW https://t.co/UYIAsfRtB8
genes.map_.jpg

Pathogenic Impact of microRNA Cotargeting in Lupus

EurekAlert!
Jan 27, 2023

A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. They identified two miRNAs that are downregulated in the disease and an uncommon situation that occurs in which multiple

Read Article
RheumNow Podcast square

Simon Says “Don’t Do This” (1.27.2022)

Jan 27, 2023

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.




  1. "Dry Synovitis" exist in juvenile arthritis pts? Study of 12 DS pts, says its different from Poly #JIA; onset 6.1 yrs

Read Article
702 #SLE pts (age 29 yrs) from India, measured plasma 25-hydroxyvitamin-D(25(OH)D) - median levels were 22.83 (13.8–31.8) ng/ml. Low Vit D(< 20) seen in 41.5%; correlated w/ age/geography, & weak neg correlation w/ weak negative correlation w/ SLEDAI2K https://t.co/EUPqJGKAhI https://t.co/MEIL5yd64n
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/RaFKTqhQjN https://t.co/hH0NcpOoyx
Inpatient health care utilization studied in 341 #SLE pts vs 341 non-SLE. SLE had more hospitalizations (30 vs 10/100PY) and more ED visit (HR 2.71) and Hospital readmission rates (32% vs. 21%, p = 0.017) https://t.co/vsW7Ol9b4O https://t.co/hpmcFuF8Pm
pregnant.baby_.hands_.jpg

Variable Pregnancy Outcomes with Belimumab in SLE

Jan 24, 2023

An analysis of the belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports looked at outcomes in pregnant systemic lupus erythematosus (SLE) exposed to belimumab reported there are few pregnancies and confounding disease and comorbidity factors

Read Article
eye%20exa.jpg (keep)

Hydroxychloroquine Dose and Risk for Incident Retinopathy

Jan 18, 2023

A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.



The study aimed to assess the long-term risk for incident hydroxychloroquine retinopathy and examine the degree to

Read Article
Lupus Research Alliance (LRA) is pleased to announce the appointment of Stacie J. Bell, PhD as Executive Vice President to lead Lupus Therapeutics, the organization’s clinical research affiliate. Dr Bell was prev CMO of the Natl Psoriasis Foundation https://t.co/deCIo8lI5Y https://t.co/dBodyzWtsi
Join RheumNow Live in person or virtually on 3/18 and 3/19. This meeting is unlike any other meeting you attended. But don't take our word for it, last year's attendees say: "Great conference. Best in the last year. I did Hopkins, CCR, and ACR too"https://t.co/Im6xStFwOw https://t.co/NhdbkNo1jl
Worse Birth Outcomes in RA and SLE A population-based retrospective cohort study patients with RA or SLE and their infants demonstrated significant adverse pregnancy outcome, particularly the infants of women with SLE.https://t.co/oK05W8ncW0 https://t.co/3eJzHHOvXO
pregnancy,doctor,consult

Worse Birth Outcomes in RA and SLE

Jan 11, 2023

A population-based retrospective cohort study patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and their infants demonstrated significant adverse pregnancy outcome, particularly the infants of women with SLE. This included maternal/infant rehospitalization,

Read Article
Autoimmune Dz may be assoc w/ new-onset Atrial Fibrillation, esp in women. Population-based UK Biobank found significant increases for AFib in Rheumatic fever w/o CVD (HR 1.47), Crohn’ (1.23), UC(1.17), RA (1.39), PAN (1.82), SLE (1.82), PSS (2.32) https://t.co/rpIiztUfg9 https://t.co/FWmLiZ6x1S
Join us for RheumNow Live this March 18-19 in Dallas, TX! We're not like other meetings--we're answering the questions you want answered. RNL is a meeting to engage your mind and change your practice. Join us in-person or virtually!https://t.co/bMphD12Bie https://t.co/Hx0uHAIUWd
RheumNow Podcast square

2022 Rheumatology Year in Review (1-6-2023)

Jan 06, 2023

Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.

Read Article
2022,wordle

2022 Rheumatology Year in Review

Jan 05, 2023

2022 was a year of recovery, discovery, and some losses.  While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.

Read Article
Retrospective Claims analysis 1663 #SLE pts shows pts w/ lupus nephritis (LN, 2916) had higher Charlson Comorbidity scores ≥4 (72 vs 14%) & inpatient (41 vs 17%). LUPUS FLARES were more (61 vs 54%), more severe (11 vs 5%) & twice the cost https://t.co/tXI7SSalaV https://t.co/z0SorOQilb
Best of 2022: Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines https://t.co/Swf5kq6VtG https://t.co/UTIaCFpAX6
Drug-Induced Lupus from Proton Pump Inhibitors A wide range of therapies have been implicated in causing drug-induced lupus erythematosus (DIL); now it appears that proton pump inhibitors (PPIs) can be added to the list of causative drugs.https://t.co/Jp3oNUhP6c https://t.co/AcC4mM0nLM
Malar,rash,SLE, Lupus

Best of 2022: Emerging Therapeutics for Lupus

Dec 29, 2022

Impressive data on novel treatment for SLE were presented at the EULAR22 Congress. A disease that is difficult to study due to its pleomorphic presentation, unpredictable disease course, and high mortality rates, SLE is considered the dragon of all autoimmune diseases. Here are highlights of

Read Article
Three (3) Worst Drugs to use in #Lupus patients who want to be pregnant (MTX, MMF, CTX) #UTSWSLE2022 https://t.co/nBBUlWXmhw
question-mark-1872634_640.jpg

Best of 2022: Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines

In the wake of the 2016 AAOS Guidelines, rheumatologists dutifully reduced the dose HCQ take by patients with SLE to some number south of 5mg/kg per day. Though I believe the ophthalmologists correctly interpreted a 2014 paper in JAMA Ophthalmology that quoted a much-higher rate of HCQ

Read Article
Challenges in Lupus: -Mortality greatest in 1st yr -Dx Delays 6.4 yrs -Long-term complications increased 50 fold -Steroids worsen long-term outcomes -Health care costs increased 3 to 5 years prior to Dx -Mean delay in drug starts after Dx =177 days https://t.co/NPxzluJJAV https://t.co/J2uLOfeijV
Infection in lupus is suggested by very high CRP, PMN-lymph ratio (NLR) Plt-lymph ratio(PLR). Study of 104 hospitalized SLE found all very high w/ infx & Combined cutoffs of CRP >20 mg/L, NLR >3.5, PLR >151 had 87 sensitivity & 81% specificity for infx https://t.co/2ycSGhnHeK https://t.co/VZsGAK2hFs
×